AZNAstraZenecaRunning, no new patients
A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)
Locally Advanced Cervical Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 37 (final count)
- Started
- Mar 31, 2025
- Main results expected
- Mar 13, 2028
- Fully finished
- Mar 13, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free Survival at 24 months (PFS24)
Measured over: From date of first dose until 24 months.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06943833 · record last updated 2026-08-18 · checked 2026-11-09 15:47 UTC